Open AccessTrends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs
Esmo OpenPeer ReviewedM Franken +172021Journals
The content you want is available to Zendy users.
Already have an account? Sign inHaving issues? Contact support